Adlai Nortye Ltd. will present at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics on October 25, 2025, in Boston, MA. The presentation will focus on their CEACAM5-targeting antibody drug conjugate, AN4035, armed with a proprietary pan-RAS(ON) inhibitor payload. Adlai Nortye is a clinical-stage biotechnology company developing innovative cancer therapies, with a global presence in the U.S. and China. They are advancing drug candidates targeting PD-1/L1 modulation and RAS-driven cancers. The Company will provide more details on AN4035 once the abstract is released on October 22, 2025.

Read more at GlobeNewswire: Adlai Nortye to Present Short Talk at AACR-NCI-EORTC